...
search icon
sage-img

Sage Therapeutic, Common Stock

SAGE

NMQ

$7.696

+$2.15

(38.74%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$458.80M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
9.12M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.92
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.62 L
$27.68 H
$7.696

About Sage Therapeutic, Common Stock

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameSAGESectorS&P500
1-Week Return-9.61%0.49%-1.93%
1-Month Return-0.36%-3.1%-3.69%
3-Month Return-12.87%-8.59%0.82%
6-Month Return-49.68%-4.57%3.51%
1-Year Return-78.15%-0.94%21.91%
3-Year Return-86.84%2.88%24.73%
5-Year Return-92.81%35.84%78.4%
10-Year Return-87.33%98.8%187.28%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue6.87M1.11B6.31M7.69M86.45M[{"date":"2019-12-31","value":0.62,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.57,"profit":true},{"date":"2022-12-31","value":0.69,"profit":true},{"date":"2023-12-31","value":7.76,"profit":true}]
Cost of Revenue400.00K565.00K553.00K813.00K2.16M[{"date":"2019-12-31","value":18.53,"profit":true},{"date":"2020-12-31","value":26.17,"profit":true},{"date":"2021-12-31","value":25.61,"profit":true},{"date":"2022-12-31","value":37.66,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit6.47M1.11B5.75M6.87M84.30M[{"date":"2019-12-31","value":0.58,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":0.52,"profit":true},{"date":"2022-12-31","value":0.62,"profit":true},{"date":"2023-12-31","value":7.57,"profit":true}]
Gross Margin94.18%99.95%91.23%89.42%97.50%[{"date":"2019-12-31","value":94.22,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":91.28,"profit":true},{"date":"2022-12-31","value":89.47,"profit":true},{"date":"2023-12-31","value":97.55,"profit":true}]
Operating Expenses714.59M489.67M466.66M553.86M630.76M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":68.52,"profit":true},{"date":"2021-12-31","value":65.3,"profit":true},{"date":"2022-12-31","value":77.51,"profit":true},{"date":"2023-12-31","value":88.27,"profit":true}]
Operating Income(708.12M)596.23M(460.91M)(546.99M)(579.85M)[{"date":"2019-12-31","value":-118.77,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-77.3,"profit":false},{"date":"2022-12-31","value":-91.74,"profit":false},{"date":"2023-12-31","value":-97.25,"profit":false}]
Total Non-Operating Income/Expense55.69M19.44M5.90M28.39M74.43M[{"date":"2019-12-31","value":74.82,"profit":true},{"date":"2020-12-31","value":26.12,"profit":true},{"date":"2021-12-31","value":7.93,"profit":true},{"date":"2022-12-31","value":38.15,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(680.24M)606.07M(457.89M)(532.78M)(541.49M)[{"date":"2019-12-31","value":-112.24,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false}]
Income Taxes(30.09M)15.52M(7.07M)(29.52M)(5.36M)[{"date":"2019-12-31","value":-193.91,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-45.53,"profit":false},{"date":"2022-12-31","value":-190.24,"profit":false},{"date":"2023-12-31","value":-34.53,"profit":false}]
Income After Taxes(650.15M)590.56M(450.83M)(503.27M)(536.13M)[{"date":"2019-12-31","value":-110.09,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-76.34,"profit":false},{"date":"2022-12-31","value":-85.22,"profit":false},{"date":"2023-12-31","value":-90.78,"profit":false}]
Income From Continuous Operations(680.24M)606.07M(457.89M)(532.78M)(655.93M)[{"date":"2019-12-31","value":-112.24,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-75.55,"profit":false},{"date":"2022-12-31","value":-87.91,"profit":false},{"date":"2023-12-31","value":-108.23,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(650.15M)606.07M(450.83M)(503.27M)(541.49M)[{"date":"2019-12-31","value":-107.27,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-74.38,"profit":false},{"date":"2022-12-31","value":-83.04,"profit":false},{"date":"2023-12-31","value":-89.34,"profit":false}]
EPS (Diluted)(13.38)11.64(7.80)(8.98)(10.31)[{"date":"2019-12-31","value":-114.95,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-67.01,"profit":false},{"date":"2022-12-31","value":-77.15,"profit":false},{"date":"2023-12-31","value":-88.57,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

SAGE
Cash Ratio 9.42
Current Ratio 10.02
Quick Ratio 10.31

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

SAGE
ROA (LTM) -29.62%
ROE (LTM) -49.34%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

SAGE
Debt Ratio Lower is generally better. Negative is bad. 0.11
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.89

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

SAGE
Trailing PE NM
Forward PE NM
P/S (TTM) 3.19
P/B 0.62
Price/FCF NM
EV/R 2.10
EV/Ebitda NM
PEG 0.74

FAQs

What is Sage Therapeutic share price today?

Sage Therapeutic (SAGE) share price today is $7.696

Can Indians buy Sage Therapeutic shares?

Yes, Indians can buy shares of Sage Therapeutic (SAGE) on Vested. To buy Sage Therapeutic from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in SAGE stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Sage Therapeutic be purchased?

Yes, you can purchase fractional shares of Sage Therapeutic (SAGE) via the Vested app. You can start investing in Sage Therapeutic (SAGE) with a minimum investment of $1.

How to invest in Sage Therapeutic shares from India?

You can invest in shares of Sage Therapeutic (SAGE) via Vested in three simple steps:

  • Click on Sign Up or Invest in SAGE stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Sage Therapeutic shares
What is Sage Therapeutic 52-week high and low stock price?

The 52-week high price of Sage Therapeutic (SAGE) is $27.68. The 52-week low price of Sage Therapeutic (SAGE) is $4.62.

What is Sage Therapeutic price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Sage Therapeutic (SAGE) is

What is Sage Therapeutic price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Sage Therapeutic (SAGE) is 0.62

What is Sage Therapeutic dividend yield?

The dividend yield of Sage Therapeutic (SAGE) is 0.00%

What is the Market Cap of Sage Therapeutic?

The market capitalization of Sage Therapeutic (SAGE) is $458.80M

What is Sage Therapeutic’s stock symbol?

The stock symbol (or ticker) of Sage Therapeutic is SAGE

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top